Antiviral drug discovery for the treatment of COVID-19 infections

TI Ng, I Correia, J Seagal, DA DeGoey, MR Schrimpf… - Viruses, 2022 - mdpi.com
The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus …

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

M Kumari, RM Lu, MC Li, JL Huang, FF Hsu… - Journal of biomedical …, 2022 - Springer
The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis,
presenting a broad range of challenges. To help address some of the main problems, the …

[HTML][HTML] On the road to ending the COVID-19 pandemic: Are we there yet?

JB Case, ES Winkler, JM Errico, MS Diamond - Virology, 2021 - Elsevier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into the human
population in late 2019 and caused the global COVID-19 pandemic. SARS-CoV-2 has …

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

C Liu, Q Zhou, Y Li, LV Garner, SP Watkins, LJ Carter… - 2020 - ACS Publications
Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2
virus, this disease has spread rapidly around the globe. Considering the potential threat of a …

A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic

CD Funk, C Laferrière, A Ardakani - Frontiers in pharmacology, 2020 - frontiersin.org
A novel coronavirus SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) has
entered the human population and has spread rapidly around the world in the first half of …

New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals

J Chen, H Lu - Bioscience trends, 2021 - jstage.jst.go.jp
Despite strict control measures implemented worldwide, the COVID-19 pandemic continues
to rage. Several drugs, including lopinavir/ritonavir, hydroxychloroquine, dexamethasone …

Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: from mechanistic studies to clinical trials for COVID-19

J Huang, W Song, H Huang, Q Sun - Journal of clinical medicine, 2020 - mdpi.com
An outbreak of novel coronavirus-related pneumonia COVID-19, that was identified in
December 2019, has expanded rapidly, with cases now confirmed in more than 211 …

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics

L Chitsike, P Duerksen-Hughes - Virology Journal, 2021 - Springer
The COVID-19 pandemic has put healthcare infrastructures and our social and economic
lives under unprecedented strain. Effective solutions are needed to end the pandemic while …

Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities

R Cannalire, C Cerchia, AR Beccari… - Journal of medicinal …, 2020 - ACS Publications
The newly emerged coronavirus, called SARS-CoV-2, is the causing pathogen of pandemic
COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is …

Inhibitors of sars-cov-2 plpro

DJ Calleja, G Lessene, D Komander - Frontiers in chemistry, 2022 - frontiersin.org
The emergence of SARS-CoV-2 causing the COVID-19 pandemic, has highlighted how a
combination of urgency, collaboration and building on existing research can enable rapid …